Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

portfolio strategy

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Avalere Health

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Avalere Health

- PMLiVE

Almirall and CRG announce non-melanoma skin cancer research collaboration

The partners will jointly develop novel preclinical models to identify new treatments for NMSC

- PMLiVE

Putting Skin in the Game at AAD 2023

AAD has wrapped up in New Orleans, and the Medscape team have returned home from another successful conference.During the conference, Medscape hosted one educational symposium, Reframing the Management Approach for...

Medscape Education Global

- PMLiVE

LEO Pharma enters clinical trial partnership with ICON

The collaboration will focus on advancing clinical trial execution within medical dermatology

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Research Partnership

- PMLiVE

Boehringer’s Spevigo receives EC approval for generalised pustular psoriasis flares

Trial showed 54% of patients were free of pustules one week after a single dose

- PMLiVE

UCB’s Epicensus programme highlights need to address psoriasis care gap

The programme was published in Dermatology and Therapy

- PMLiVE

Sanofi and Regeneron’s Dupixent granted EC approval for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema study

There are no topical treatments specifically developed and approved for moderate-to-severe CHE

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links